您是第 10303193 位 欢迎访问 中乔新舟官网 ! 全国免费电话:400-038-9959 我的购物车(0) 注 册 / 登 录
扫码关注公众号
您当前的位置:首页 > 产品中心

Calu-1人肺癌细胞 (STR鉴定)

英文名:Calu-1
货号:ZQ0394
价格:¥1800.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

Calu-1人肺癌细胞 (STR鉴定)

¥1800.00
+

Calu-1人肺癌细胞专用培养基

¥350.00 ¥500.00

配套完培,组合使用,省时省力!

=

细胞套餐惊爆价

¥2150 ¥2300.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

Calu-1人肺癌细胞

货号

ZQ0394

产品介绍

Calu-1 是一种表现出上皮形态的细胞系,从一名 47 岁的表皮样癌白人男性患者的肺部分离出来,其超微结构特征包括众多微绒毛,显著的RER(粗面内质网),溶酶体,脂包含体,无病毒颗粒, 含ras (H-ras)癌基因,已广泛应用于肺癌生物学、药物筛选和细胞毒性研究。Calu-1细胞表达肺上皮细胞特有的几种标志物,已成为研究肺癌发生和治疗耐药分子通路的有价值的模型。
Calu-1细胞以其高增殖率和培养稳健性而闻名,使其适合体外实验设置。它保留了一些典型癌细胞的染色体异常,其中包括7号和20号染色体的多个副本,这证明了它在遗传学和细胞遗传学研究中的实用性。该细胞系还分别表现出KRAS和TP53等关键癌基因和肿瘤抑制基因的突变,这是肺癌研究中特别感兴趣的基因。这些遗传特征使Calu-1成为研究遗传改变对癌症进展的影响以及在受控环境中测试靶向治疗效果的有用工具。

种属

性别/年龄

组织

肺;转移灶:肋膜

疾病

III期,表皮瘤

细胞类型

肿瘤细胞 

形态学

上皮的

生长方式

贴壁

倍增时间

大约37~49.8小时 

培养基和添加剂

McCOY's 5A(品牌:中乔新舟  货号:ZQ-1000+10%胎牛血清(中乔新舟 货号:ZQ0500+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0394

生物安全等级

BSL-1

STR位点信息

Amelogenin: X
D5S818:10,12
D13S317: 11,12
D7S820: 9,10
D16S539: 11
vWA: 15,16
TH01: 9,9.3
TPOX: 8
CSF1PO: 10
D19S433: 13,15
D21S11: 28
D18S51: 14,17 

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

 ***

基因表达

 ***

保藏机构

ATCC; HTB-54 ECACC; 93120818

供应限制

仅供科研使用

货号

ZQ0394

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


DOI=10.1007/978-1-4757-1647-4_5
Fogh J., Trempe G.L.
New human tumor cell lines.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)


PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)


PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)


PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)


PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)


PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)


PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)


PubMed=8385084; DOI=10.1111/j.1349-7006.1993.tb02851.x
Suzuki S., Takahashi T., Nakamura S., Koike K., Ariyoshi Y., Takahashi T., Ueda R.
Alterations of integrin expression in human lung cancer.
Jpn. J. Cancer Res. 84:168-174(1993)


PubMed=7972006; DOI=10.1073/pnas.91.23.11045
Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.
Mutations and altered expression of p16INK4 in human cancer.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)


PubMed=7736387; DOI=10.1002/1097-0142(19950515)75:10<2442::AID-CNCR2820751009>3.0.CO;2-Q
Campling B.G., Sarda I.R., Baer K.A., Pang S.C., Baker H.M., Lofters W.S., Flynn T.G.
Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer.
Cancer 75:2442-2451(1995)


PubMed=11583962; DOI=10.1016/S0002-9440(10)62521-7
Haruki N., Harano T., Masuda A., Kiyono T., Takahashi T., Tatematsu Y., Shimizu S., Mitsudomi T., Konishi H., Osada H., Fujii Y., Takahashi T.
Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation.
Am. J. Pathol. 159:1345-1352(2001)


PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)


PubMed=12794755; DOI=10.1002/ijc.11184
Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T., Mitsudomi T.
RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.
Int. J. Cancer 106:45-51(2003)


PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)


PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)


PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112
Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Cancer Discov. 2:798-811(2012)


PubMed=24002593; DOI=10.1038/bjc.2013.452
Wu D., Pang Y., Wilkerson M.D., Wang D., Hammerman P.S., Liu J.S.
Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity.
Br. J. Cancer 109:1599-1608(2013)


PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqx...
联系我们 / Contact
电 话:021-56760357;021-56760351
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved. 网站地图

沪公网安备 31011002001038号

技术支持:攸攸网络 沪ICP备14008091号